Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 36.17 USD -4.24%
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one SUPN stock under the Base Case scenario is 38.45 USD. Compared to the current market price of 36.17 USD, Supernus Pharmaceuticals Inc is Undervalued by 6%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SUPN Intrinsic Value
38.45 USD
Undervaluation 6%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Supernus Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SUPN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SUPN?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Supernus Pharmaceuticals Inc

Provide an overview of the primary business activities
of Supernus Pharmaceuticals Inc.

What unique competitive advantages
does Supernus Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Supernus Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Supernus Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Supernus Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Supernus Pharmaceuticals Inc.

Provide P/S
for Supernus Pharmaceuticals Inc.

Provide P/E
for Supernus Pharmaceuticals Inc.

Provide P/OCF
for Supernus Pharmaceuticals Inc.

Provide P/FCFE
for Supernus Pharmaceuticals Inc.

Provide P/B
for Supernus Pharmaceuticals Inc.

Provide EV/S
for Supernus Pharmaceuticals Inc.

Provide EV/GP
for Supernus Pharmaceuticals Inc.

Provide EV/EBITDA
for Supernus Pharmaceuticals Inc.

Provide EV/EBIT
for Supernus Pharmaceuticals Inc.

Provide EV/OCF
for Supernus Pharmaceuticals Inc.

Provide EV/FCFF
for Supernus Pharmaceuticals Inc.

Provide EV/IC
for Supernus Pharmaceuticals Inc.

Show me price targets
for Supernus Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Supernus Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Supernus Pharmaceuticals Inc?

What are the Net Income projections
for Supernus Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Supernus Pharmaceuticals Inc?

What are the EPS projections
for Supernus Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Supernus Pharmaceuticals Inc?

What are the EBIT projections
for Supernus Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Supernus Pharmaceuticals Inc?

Compare the revenue forecasts
for Supernus Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Supernus Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Supernus Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Supernus Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Supernus Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Supernus Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Supernus Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Supernus Pharmaceuticals Inc.

Provide ROE
for Supernus Pharmaceuticals Inc.

Provide ROA
for Supernus Pharmaceuticals Inc.

Provide ROIC
for Supernus Pharmaceuticals Inc.

Provide ROCE
for Supernus Pharmaceuticals Inc.

Provide Gross Margin
for Supernus Pharmaceuticals Inc.

Provide Operating Margin
for Supernus Pharmaceuticals Inc.

Provide Net Margin
for Supernus Pharmaceuticals Inc.

Provide FCF Margin
for Supernus Pharmaceuticals Inc.

Show all solvency ratios
for Supernus Pharmaceuticals Inc.

Provide D/E Ratio
for Supernus Pharmaceuticals Inc.

Provide D/A Ratio
for Supernus Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Supernus Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Supernus Pharmaceuticals Inc.

Provide Quick Ratio
for Supernus Pharmaceuticals Inc.

Provide Current Ratio
for Supernus Pharmaceuticals Inc.

Provide Cash Ratio
for Supernus Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Supernus Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Supernus Pharmaceuticals Inc?

What is the current Free Cash Flow
of Supernus Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Supernus Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Supernus Pharmaceuticals Inc

Current Assets 640m
Cash & Short-Term Investments 403.2m
Receivables 145.4m
Other Current Assets 91.4m
Non-Current Assets 702.7m
PP&E 38m
Intangibles 657.2m
Other Non-Current Assets 7.6m
Current Liabilities 291.5m
Accounts Payable 6.4m
Accrued Liabilities 238.5m
Other Current Liabilities 46.6m
Non-Current Liabilities 44m
Other Non-Current Liabilities 44m
Efficiency

Earnings Waterfall
Supernus Pharmaceuticals Inc

Revenue
652m USD
Cost of Revenue
-71.4m USD
Gross Profit
580.5m USD
Operating Expenses
-521.3m USD
Operating Income
59.3m USD
Other Expenses
447k USD
Net Income
59.7m USD

Free Cash Flow Analysis
Supernus Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SUPN Profitability Score
Profitability Due Diligence

Supernus Pharmaceuticals Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
52/100
Profitability
Score

Supernus Pharmaceuticals Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

SUPN Solvency Score
Solvency Due Diligence

Supernus Pharmaceuticals Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Long-Term Solvency
Low D/E
High Altman Z-Score
85/100
Solvency
Score

Supernus Pharmaceuticals Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SUPN Price Targets Summary
Supernus Pharmaceuticals Inc

Wall Street analysts forecast SUPN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUPN is 40.04 USD with a low forecast of 36.36 USD and a high forecast of 45.15 USD.

Lowest
Price Target
36.36 USD
1% Upside
Average
Price Target
40.04 USD
11% Upside
Highest
Price Target
45.15 USD
25% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SUPN?

Click here to dive deeper.

Dividends

Supernus Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SUPN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SUPN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

2B USD

Dividend Yield

0%

Description

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 575 full-time employees. The company went IPO on 2010-12-28. The firm is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.

Contact

MARYLAND
Rockville
9715 Key West Avenue
+13018382500.0
www.supernus.com

IPO

2010-12-28

Employees

575

Officers

Founder, President, CEO, Secretary & Director
Mr. Jack A. Khattar M.B.A.
Senior VP & CFO
Mr. Timothy C. Dec
Chief Scientific Officer & Senior VP of Intellectual Property
Dr. Padmanabh P. Bhatt Ph.D.
Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs
Mr. Frank Mottola
Senior VP of Research & Development and Chief Medical Officer
Dr. Jonathan Rubin M.B.A., M.D.
Compliance Officer
Mr. Kevin T. Anderson Esq.
Show More
Senior Vice President of Marketing, Commercial Operations & Market Access
Dr. Todd Horich M.B.A., Ph.D.
Senior Vice President of Sales
Mr. Taylor Raiford
Senior Vice President of Corporate Development
Dr. Bryan A. Roecklein Ph.D.
Senior Vice President of Supply Chain
Mr. Jeff Bozick
Show Less

See Also

Discover More
What is the Intrinsic Value of one SUPN stock?

The intrinsic value of one SUPN stock under the Base Case scenario is 38.45 USD.

Is SUPN stock undervalued or overvalued?

Compared to the current market price of 36.17 USD, Supernus Pharmaceuticals Inc is Undervalued by 6%.

Back to Top